Edgewise Therapeutics, Inc. (EWTX)
NASDAQ: EWTX · Real-Time Price · USD
14.89
+0.07 (0.47%)
At close: May 13, 2025, 4:00 PM
14.50
-0.39 (-2.62%)
Pre-market: May 14, 2025, 8:05 AM EDT
Edgewise Therapeutics Stock Forecast
Stock Price Forecast
The 8 analysts with 12-month price forecasts for Edgewise Therapeutics stock have an average target of 40.13, with a low estimate of 14 and a high estimate of 52. The average target predicts an increase of 169.51% from the current stock price of 14.89.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Edgewise Therapeutics stock from 8 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 5 | 5 | 5 | 6 | 5 | 5 |
| Hold | 0 | 1 | 1 | 1 | 2 | 2 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 7 | 7 | 8 | 8 | 8 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Wedbush | Wedbush | Buy Maintains $43 | Buy | Maintains | $43 | +188.78% | Apr 21, 2025 |
| RBC Capital | RBC Capital | Buy Maintains $56 → $52 | Buy | Maintains | $56 → $52 | +249.23% | Apr 3, 2025 |
| Scotiabank | Scotiabank | Buy → Hold Downgrades $50 → $14 | Buy → Hold | Downgrades | $50 → $14 | -5.98% | Apr 3, 2025 |
| Piper Sandler | Piper Sandler | Buy Maintains $51 | Buy | Maintains | $51 | +242.51% | Apr 2, 2025 |
| Scotiabank | Scotiabank | Buy Initiates $50 | Buy | Initiates | $50 | +235.80% | Mar 7, 2025 |
Financial Forecast
Revenue This Year
n/a
from 516.72M
Revenue Next Year
n/a
EPS This Year
-1.90
from -1.45
EPS Next Year
-2.09
from -1.90
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | n/a | 33.6M | 111.2M | ||
| Avg | n/a | 6.5M | 51.3M | ||
| Low | n/a | n/a | 6.6M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | 1,621.1% | ||
| Avg | - | - | 693.7% | ||
| Low | - | - | 2.6% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -1.68 | -1.51 | -1.46 | ||
| Avg | -1.90 | -2.09 | -2.12 | ||
| Low | -2.05 | -2.44 | -2.99 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.